- Home
- SQM vs EXEL Comparison
SQM vs EXEL Comparison
Compare SQM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQM | EXEL |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 11.1B |
| IPO Year | 1993 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SQM | EXEL |
|---|---|---|
| Price | $61.26 | $44.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 24 |
| Target Price | ★ $50.81 | $44.73 |
| AVG Volume (30 Days) | 2.1M | ★ 2.5M |
| Earning Date | 11-18-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 1.84 | ★ 2.38 |
| Revenue | ★ $4,326,111,000.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.14 |
| Revenue Next Year | $22.11 | $12.51 |
| P/E Ratio | $33.36 | ★ $18.67 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $29.36 | $31.90 |
| 52 Week High | $65.65 | $49.62 |
Technical Indicators
Market Signals| Indicator | SQM | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 63.52 |
| Support Level | $59.97 | $43.00 |
| Resistance Level | $65.65 | $44.79 |
| Average True Range (ATR) | 2.39 | 1.03 |
| MACD | -0.26 | 0.06 |
| Stochastic Oscillator | 48.65 | 83.48 |
Price Performance
Historical ComparisonAbout SQM Sociedad Quimica y Minera S.A.
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.